Exogenous Biliverdin Ameliorates Ischemia-Reperfusion Injury in Small-For-Size Rat Liver Grafts

L.-M. Tang,Y.-P. Wang,K. Wang,L.-Y. Pu,F. Zhang,X.-C. Li,L.-B. Kong,B.-C. Sun,G.-Q. Li,X.-H. Wang

DOI: https://doi.org/10.1016/j.transproceed.2006.11.032

IF: 1.014

2007-01-01

Transplantation Proceedings

Abstract:Objective. This study sought to investigate the protective potential of exogenous biliverdin (BV) for small-for-size rat liver transplants.Methods and results. We employed a rat orthotopic liver transplantation model using small-for-size grafts. BV (50 mu mol/kg, intravenously) given to the recipient immediately before reperfusion increased 7-day survival rates (90% vs 40% in controls) and significantly diminished hepatocyte injury, as compared with a control group. These effects correlated with improved liver function and preserved hepatic architecture. BV adjuvant increased antioxidant ability, suppressed proinflammatory tumor necrosis factor-a expression, down-regulated proapoptotic molecules (cytochrome C and caspase-3), and inhibited most apoptotic cells. After reperfusion, there was a significant increase of c-Jun NH2-terminal kinase (JNK) activation and AP-1 binding ability. BV treatment effectively repressed JNK/AP-1 activation, indicating that a beneficial effect of BV treatment may be related to suppression of the JNK/AP-1 pathway.Conclusions. BV treatment alleviated ischemia-reperfusion injury at least in part via inhibition of the proinflammatory and proapoptotic JNK/AP-1 pathway. Our findings provide a rationale for a novel therapeutic approach using BV to maximize the availability of small-for-size liver grafts.